PRAXライブシグナル | Getagraph.comで利益を最大化

買う 107862 min ago

@ $42.09

発行日: 15 2月 2024 @ 04:09

リターン: 34.18%

前回のシグナル: 2月 15 - 00:24

前回のシグナル: 売る

リターン: -4.89 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance...

Stats
本日の出来高	34 635.00
平均出来高	203 709
時価総額	965.04M
EPS	$0 ( 2024-03-05 )
次の収益日	( $-2.01 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.02
ATR14	$0.200 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mastrocola Lauren	Sell	48	Common Stock
2024-02-12	Nemiroff Alex	Sell	51	Common Stock
2024-02-12	Souza Marcio	Sell	271	Common Stock
2024-01-12	Kelly Timothy Edwin	Buy	30 000	Stock Option (Right to Buy)
2024-01-12	Souza Marcio	Buy	100 000	Stock Option (Right to Buy)

INSIDER POWER
98.10
Last 99 transactions
Buy: 3 195 196 \| Sell: 875 304

ボリューム相関

長: -0.15 (neutral)

短: -0.91 (very strong negative)

Signal:(48.713) Neutral

Praxis Precision 相関

10 最も正の相関
EUSG	0.899
AAWW	0.893
VICR	0.884
CVCY	0.865
CASH	0.861
BPRN	0.859
PXLW	0.848
SMSI	0.842
IMAB	0.839
CIZN	0.837

10 最も負の相関
MOSY	-0.87
APOP	-0.826

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Praxis Precision 相関 - 通貨/商品

-0.37
( neutral )

-0.64
( weak negative )

0.82
( strong )

0.47
( neutral )

0.40
( neutral )

0.85
( strong )

Praxis Precision 財務諸表

Annual	2023
収益:	$2.45M
総利益:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2023
収益:	$2.45M
総利益:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2022
収益:	$0
総利益:	$-1.17M (0.00 %)
EPS:	$-69.33

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.74

Financial Reports:

No articles found.

Praxis Precision

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.